News

Nativis Logo (r) 2016_featured

Nativis Publishes Abstract on Voyager System for Patients with rGBM at 2017 ASCO Annual Meeting

Nativis, Inc., a clinical stage life science bio-electronic company developing non-invasive, safe and highly effective treatments for cancers and other serious diseases, today announced the release of an abstract on its Nativis Voyager® system for use in patients with recurrent glioblastoma multiforme (rGBM). The abstract will be published online during the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 2-6, 2017, in Chicago, IL. Abstracts are available to the public at www.abstract.asco.org.

The Nativis Voyager system is a non-invasive investigational device that delivers ultra-low radio frequency energy (ulRFE™) profiles to the brain. The ulRFE profiles are derived from changes in molecular electrostatic surface potential. The Voyager system is being studied in a first-in-human study to assess the safety and feasibility of treatment for recurrent glioblastoma multiforme.

In the publication entitled “A Feasibility Study of the Nativis Voyager™ System in Patients with Recurrent Glioblastoma Multiforme (GBM): Interim results of first-in-human study,” the authors, Garni Barkhoudarian, Charles Cobbs, Edward McClay, Brian Vaillant, J. Paul Duic, L. Burt Nabors,

Benjamin M. Ellingson, Deborah Sheffield, Santosh Kesari, highlighted the interim results of the first part of a 2-stage study. This first study enrolled 14 patients at four clinical trial sites across the United States, in which 11 subjects were followed per protocol, with 3 subjects dropping out for reasons not associated with the study. In the first two months of treatment, 2 of the 11 subjects were Avastin-naïve and exhibited a partial response. After 6 cycles (24 weeks) of treatment, the local sites reported 2 patients were progression free.  No serious adverse events associated with the investigational therapy were reported.

“We are honored to have our first-in-human study recognized by ASCO as we continue to pioneer our novel ulRFE technology,” commented Chris Rivera, Nativis President and Chief Executive Officer. “The interim data from this feasibility study provide an encouraging outlook for the Voyager system, which appears to be feasible and safe for the treatment of recurrent GBM. With these data in hand, we look forward to moving forward into the second and final stage of the study.”

About Nativis, Inc.

Founded in 2002 and headquartered in Seattle, WA, Nativis is a clinical-stage bio-electronics company. Nativis has invented and patented a groundbreaking technology that utilizes precisely targeted, ultra-low radio frequency energy (ulRFE) to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use non-invasive investigational device called Nativis Voyager®. The company’s goal is to transform disease treatment on a global scale with ulRFE, which can potentially be applied to a wide range of conditions and other health-related needs (including agriculture, bio-fuels and veterinary medicine, to name a few). Nativis’ initial focus is on the treatment of patients with brain cancer (initially, recurrent glioblastoma), who are not well served by conventional standard of care therapies, which often result in poor outcomes and devastating side effects. Additional pre-clinical work is being completed for melanoma, lung cancer, liver cancer, inflammatory disease and chronic pain.  Nativis Voyager® ulRFE™ System for rGBM is an investigational medical device. Limited by Federal (or United States) law to investigational use only.

Investor Relations Contact:

Lee Roth / Tram Bui

lroth@theruthgroup.com / tbui@theruthgroup.com

646-536-7012 / 7035

Media Relations Contact:

Aaron Blank / Amber Benson

ablank@feareygroup.com / abenson@feareygroup.com

206-343-1543

Back to News